ZHIGANG XIA1,#, MENGYAO TIAN1,#, YUCAI CHENG1, WENFANG YI1, ZEFAN DU1,2, TIANWEN LI1,2, YUCHEN WEN1, LINDI LI1,2, YONG LIU1,2,*, CHUN CHEN1,*
Oncology Research, Vol.32, No.6, pp. 1109-1118, 2024, DOI:10.32604/or.2024.049792
- 23 May 2024
Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapy has achieved marked therapeutic success in ameliorating hematological malignancies. However, there is an extant void in the clinical guidelines concerning the most effective chemotherapy regimen prior to chimeric antigen receptor T (CAR-T) cell therapy, as well as the optimal timing for CAR-T cell infusion post-chemotherapy. Materials and Methods: We employed cell-derived tumor xenograft (CDX) murine models to delineate the optimal pre-conditioning chemotherapy regimen and timing for CAR-T cell treatment. Furthermore, transcriptome sequencing was implemented to identify the therapeutic targets and elucidate the underlying mechanisms governing the treatment regimen.… More >
Login
Register
